Progression-Free Survival Improved With Nivolumab + AVD in Hodgkin Lymphoma
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 16, 2024 -- For patients with stage III or IV Hodgkin lymphoma, nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) yields longer progression-free survival (PFS) than brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (BV+AVD), according to a study published online Oct. 16 in the New England Journal of Medicine.
Alex F. Herrera, M.D., from the City of Hope Comprehensive Cancer Center in Duarte, California, and colleagues conducted a phase 3, multicenter, randomized trial involving patients at least 12 years of age with stage III or IV newly diagnosed Hodgkin lymphoma. A total of 994 patients were randomly assigned to BV+AVD or N+AVD; 970 were included in the intention-to-treat population for an efficacy analysis.
The researchers found that the threshold for efficacy was crossed at the second planned interim analysis, with a median follow-up of 12.1 months, indicating that PFS was significantly improved with N+AVD versus BV+AVD (hazard ratio for progression or death, 0.48). The analysis was repeated with longer follow-up, and the two-year PFS was 92 and 83 percent with N+AVD and BV+AVD, respectively, with a median follow-up of 2.1 years (hazard ratio for disease progression or death, 0.45). Immune-related adverse events occurred rarely with nivolumab; more treatment discontinuation was seen with BV.
"On the basis of the clinically meaningful improvement in progression-free survival and excellent side-effect profile of N+AVD, the opportunity to avoid potentially toxic consolidative radiation therapy, and the decreased drug-acquisition and supportive-care costs, N+AVD should be a strong candidate for primary treatment in adolescent and adult patients with stage III or IV Hodgkin lymphoma," the authors write.
Bristol Myers Squibb and SeaGen provided drugs used in the trial.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Risk for Lymphoma, Skin Cancer Increased in Individuals With Tattoos
FRIDAY, March 7, 2025 -- Tattooed individuals have an increased risk for lymphoma and skin cancers, according to a study recently published in BMC Public Health. Signe Bedsted...
Obesity at Pediatric Cancer Diagnosis Linked to Inferior Survival
MONDAY, Jan. 13, 2025 -- Obesity at cancer diagnosis is associated with inferior survival among children aged 2 to 18 years, according to a study published online Jan. 13 in...
Position Statement Developed for Managing Blood Cancers in Pregnancy
WEDNESDAY, Jan. 8, 2025 -- In a new position statement published online Jan. 3 in The Lancet Haematology, guidelines are presented for the management of acute leukemia and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.